Small Bowel Carcinomas in Coeliac or Crohn’s Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian Consortium
Open Access
- 1 April 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 11 (8), 942-953
- https://doi.org/10.1093/ecco-jcc/jjx031
Abstract
An increased risk of small bowel carcinoma [SBC] has been reported in coeliac disease [CD] and Crohn’s disease [CrD]. We explored clinico-pathological, molecular, and prognostic features of CD-associated SBC [CD-SBC] and CrD-associated SBC [CrD-SBC] in comparison with sporadic SBC [spo-SBC]. A total of 76 patients undergoing surgical resection for non-familial SBC [26 CD-SBC, 25 CrD-SBC, 25 spo-SBC] were retrospectively enrolled to investigate patients’ survival and histological and molecular features including microsatellite instability [MSI] and KRAS/NRAS, BRAF, PIK3CA, TP53, HER2 gene alterations. CD-SBC showed a significantly better sex-, age-, and stage-adjusted overall and cancer-specific survival than CrD-SBC, whereas no significant difference was found between spo-SBC and either CD-SBC or CrD-SBC. CD-SBC exhibited a significantly higher rate of MSI and median tumour-infiltrating lymphocytes [TIL] than CrD-SBC and spo-SBC. Among the whole SBC series, both MSI─which was the result of MLH1 promoter methylation in all but one cases─and high TIL density were associated with improved survival at univariable and stage-inclusive multivariable analysis. However, only TILs retained prognostic power when clinical subgroups were added to the multivariable model. KRAS mutation and HER2 amplification were detected in 30% and 7% of cases, respectively, without prognostic implications. In comparison with CrD-SBC, CD-SBC patients harbour MSI and high TILs more frequently and show better outcome. This seems mainly due to their higher TIL density, which at multivariable analysis showed an independent prognostic value. MSI/TIL status, KRAS mutations and HER2 amplification might help in stratifying patients for targeted anti-cancer therapy.Keywords
This publication has 33 references indexed in Scilit:
- Cancers Complicating Inflammatory Bowel DiseaseThe New England Journal of Medicine, 2015
- Small Bowel Adenocarcinomas Complicating Crohnʼs Disease Are Associated With DysplasiaInflammatory Bowel Diseases, 2014
- Small bowel adenocarcinomas—existing evidence and evolving paradigmsNature Reviews Clinical Oncology, 2013
- A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare DiseaseAnnals of Surgical Oncology, 2011
- High-Resolution Array Comparative Genomic Hybridization in Sporadic and Celiac Disease–Related Small Bowel AdenocarcinomasClinical Cancer Research, 2010
- Coeliac diseaseThe Lancet, 2009
- Small Bowel Cancer in the United StatesAnnals of Surgery, 2009
- Meta‐analysis: colorectal and small bowel cancer risk in patients with Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2006
- The Role of Defective Mismatch Repair in Small Bowel Adenocarcinoma in Celiac DiseaseCancer Research, 2004
- Small bowel neoplasia in coeliac diseaseGut, 2003